Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma

Overview of attention for article published in Frontiers in oncology, September 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 10 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 7,446 followers.

New article: Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma https://t.co/nqz7LDpNiY #livercancer #oncology https://t.co/Dd61aPgCC6

26 Sep 2022

Reply Repost Favourite

New research: Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma: Lenvatinib is the first-line treatment for hepatocellular carcinoma (HCC), the most common type of primary… https://t.co/P

09 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.